October's Reader Favorites
In case you missed them, here are our top stories from October 2023 that cover upcoming therapies, groundbreaking research, and more.
While some affirm the health benefits of caffeine, like improving insulin sensitivity and blood sugar, research is mixed on whether it's detrimental for people with diabetes.
The newest study of once-weekly insulins showed that insulin icodec led to similar reductions in A1C and similar time in range compared to once-daily Tresiba (degludec).
For many years, a cure for type 1 diabetes has only been a pipe dream for the millions of people living with type 1 diabetes. New data from Vertex Pharmaceuticals on the first people to receive a revolutionary cell therapy for type 1 suggests a significant step toward a cure.
New data on the medication orforglipron – which is in development but not yet approved – shows encouraging results for both A1C and weight loss. Based on these findings, orforglipron outperforms Trulicity and holds promise as another oral option for type 2 diabetes.
People with diabetes who are U.S. citizens or permanent residents can apply for an America the Beautiful Pass, which offers access to over 2,000 parks, monuments, and landmarks. Plus, national parks’ lover Alex Day, who has lived with type 1 diabetes for 20 years, shares tips for exercising outdoors safely.